Clinical Trials | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Subscribe To Our Newsletter & Stay Updated
